- News
- Announcements
Announcements
Current & archive
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
DSD HSO No. 45
Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL)
Sustainability of inpatient psychiatric rehabilitation for adults: systematic review
Against the backdrop of an increase in disability pensions due to mental health disorders, the aim of this review was a systematic analysis of the sustainability of inpatient psychiatric/ psychosomatic rehabilitation covering an observation period of at least 12 months after discharge from rehabilitation.
Overall, included studies (1 meta-analysis, 4 RCTs, 2 pre-post studies with, and 14 without a control group) showed similar trends: the improvement between admission and discharge deteriorated to varying degrees during the catamnestic period. Nevertheless, results remained better than at admission, though. In studies on specific aftercare we observed a trend towards an improved stabilization of treatment effects.
Publication: LBI-HTA Project report No.75: https://eprints.aihta.at/1025
Contact: Brigitte Piso
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
DSD HSO No. 43
Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas
Treatment by clinical psychologists: Literature overview on training, methods of treatment and areas of application
In Austria, the ASVG (General Law on Social Security) currently includes clinical-psychological diagnostics, but not treatment by clinical psychologists. The LBI-HTA compiled a literature overview on “treatment by clinical psychologists” on behalf of the Austrian Federal Ministry of Health: Part I includes a comparison of training requirements of clinical psychologists in several countries and analyses Austrian stakeholder views systematically, part II presents a literature overview on treatment methods and indication areas in the international scientific literature.
Publication: LBI-HTA Project report No. 69a: https://eprints.aihta.at/1018
Contact: Nikolaus Patera
Publication: LBI-HTA Project report No. 69b: https://eprints.aihta.at/1019
Contact: Inanna Reinsperger
Hadron Therapy: Proton and carbon ion therapy - a review on clinical evidence of efficacy, ongoing research and reimbursement
Currently, there are about 40 facilities operating worldwide (14 in Europe) that offer hadron therapy. An additional 25 facilities (9 in Europe) are under construction and will go into operation in the coming years. In 2015, the Austrian center, MedAustron, will be opened in Wiener Neustadt. In the next 3–5 years, the capacity in Europe will approximately double. Since a supply-induced demand is to be assumed due to the considerable expansion of capacity in Europe the health policy issues – underlying this report - are: for which indications (tumor entities, stages) is evidence for a better efficacy, resp., fewer side effects through hadron therapy (proton or carbon ion therapy) already available, which clinical trials are currently running, which indications are also mentioned in guidelines, and which indications are reimbursed in other social health insurance countries.
Publication: LBI-HTA Project report No. 72: https://eprints.aihta.at/1021
Contact: Claudia Wild
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
Evidence requirements for the authorization and reimbursement of high-risk medical devices in the USA, Europe, Australia and Canada: An analysis of seven high-risk medical devices
This research first explored the authorization systems for high-risk medical devices in four selected regions (USA, Canada, Australia and Europe) of the western world. Secondly, it analyzed the clinical evidence accessible at time of market approval and decision support (HTA) for reimbursement for seven selected high-risk medical devices. The results support a change in the European authorization system towards a transparent and evidence-based regulation process: All seven medical devices have been approved in the European Union through an appointed Notified Body, only four by the Australian TGA, one each by the US-American FDA and by the Canadian TPD. In comparison to the other three regulatory systems, the number of approved devices in Europe is high, esp. if additionally taken into consideration that four further devices were also assessed by the FDA, but either rejected or not approved for general use.
Publication: LBI-HTA Project report No. 73: https://eprints.aihta.at/1017
Contact: Claudia Wild
Occupational therapy in children and adolescents. Literature review on indications, utilisation and recommendations
The frequency of prescriptions and underlying indications of occupational therapy (OT) in children and adolescents in Austria are unclear. The aim of the project was to identify fields of application and recommendations for OT as well as information on the frequency of prescriptions from (German) health insurance reports. We included 24 review articles, 20 guidelines and 4 health reports.
The results show that among many other indication areas CNS-disorders, developmental delays and ADHD were mentioned most often. Detailed, indication-specific information concerning prescription of OT for children and young people cannot be found.
Publication: LBI-HTA Project report No. 70: https://eprints.aihta.at/1016
Contact: Johanna Breuer
